Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507643 | 1.00 | CCR1 (0.74) | CCR1 | |
| SCHEMBL4492381 | 0.85 | CCR1 (1.00) | CCR1 | |
| SCHEMBL4492389 | 0.85 | CCR1 (1.00) | CCR1 | |
| SCHEMBL4503478 | 0.84 | CCR1 (0.72) | CCR1 | |
| SCHEMBL4503484 | 0.84 | CCR1 (0.72) | CCR1 | |
| SCHEMBL4497465 | 0.83 | CCR1 (0.67) | CCR1 | |
| SCHEMBL4497464 | 0.83 | CCR1 (0.67) | CCR1 | |
| SCHEMBL15164223 | 0.80 | CCR1 (0.55) | CCR1 | |
| SCHEMBL4493125 | 0.80 | CCR1 (0.62) | CCR1 | |
| SCHEMBL4493130 | 0.80 | CCR1 (0.62) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609664-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-1973880-B1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7615556-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615556-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615556-B2 | Piperazinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| EP-1973880-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Brystol-Myers Squibb Company (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
| WO-2007087585-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087585-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298845-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCR1 | CCR1 3/4885 |
| US-20070179148-A1 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCR1 | CCR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.